ES2919083R1 - Métodos de tratamiento de cáncer de próstata - Google Patents

Métodos de tratamiento de cáncer de próstata

Info

Publication number
ES2919083R1
ES2919083R1 ES202130518A ES202130518A ES2919083R1 ES 2919083 R1 ES2919083 R1 ES 2919083R1 ES 202130518 A ES202130518 A ES 202130518A ES 202130518 A ES202130518 A ES 202130518A ES 2919083 R1 ES2919083 R1 ES 2919083R1
Authority
ES
Spain
Prior art keywords
prostate cancer
cancer treatment
treatment methods
methods
prostate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES202130518A
Other languages
English (en)
Other versions
ES2919083A2 (es
Inventor
Alvaro Juan De
Josep Lluis Parra-Palau
Zariana Nikolova
Marino Jorge Di
Ellen Filvaroff
Ida Aronchik
Martina Malatesta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Quanticel Research Inc
Original Assignee
Celgene Quanticel Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Research Inc filed Critical Celgene Quanticel Research Inc
Publication of ES2919083A2 publication Critical patent/ES2919083A2/es
Publication of ES2919083R1 publication Critical patent/ES2919083R1/es
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
ES202130518A 2020-06-29 2021-06-04 Métodos de tratamiento de cáncer de próstata Pending ES2919083R1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES202030651 2020-06-29

Publications (2)

Publication Number Publication Date
ES2919083A2 ES2919083A2 (es) 2022-07-21
ES2919083R1 true ES2919083R1 (es) 2022-07-26

Family

ID=82457357

Family Applications (1)

Application Number Title Priority Date Filing Date
ES202130518A Pending ES2919083R1 (es) 2020-06-29 2021-06-04 Métodos de tratamiento de cáncer de próstata

Country Status (1)

Country Link
ES (1) ES2919083R1 (es)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012009475A1 (en) * 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1
WO2017079670A1 (en) * 2015-11-05 2017-05-11 Celgene Quanticel Research, Inc. Compositions comprising an inhibitor of lysine specific demethylase-1
WO2018031658A1 (en) * 2016-08-10 2018-02-15 Celgene Corporation Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012009475A1 (en) * 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1
WO2017079670A1 (en) * 2015-11-05 2017-05-11 Celgene Quanticel Research, Inc. Compositions comprising an inhibitor of lysine specific demethylase-1
WO2018031658A1 (en) * 2016-08-10 2018-02-15 Celgene Corporation Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FIZAZI, K. ET AL. . "Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer". . The New England Journal of Medicine , 04.06.2017, Vol. 377, Páginas 352-360 [en línea][recuperado el el 06.07.2022]. Recuperado de Internet (URL:<https://www.nejm.org/doi/pdf/10.1056/NEJMoa1704174?articleTools=true>), 0028-4793; 1533-4406 (en línea). , (DOI: 10.1056/NEJMoa1704174) Ver página 352 y conclusiones. *
HOLLEBECQUE, A. ET AL. . Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma. Clinical Cancer Research , 12.12.2020, Vol. 27, Páginas 438-446 [en línea][recuperado el 06.07.2022]. Recuperado de Internet (URL:<https://aacrjournals.org/clincancerres/article/27/2/438/83362/Phase--Study-of-Lysine-Specific-Demethylase-1>), 1078-0432; 1557-3265 (en línea), (DOI: 10.1158/1078-0432.CCR-20-2380) Ver página 438, resumen; página 441, tabla 1. *
KU, S.-Y. ET AL. . "Towards precision oncology in advanced prostate cancer". . Nature Reviews. Urology , 07.10.2019, Vol. 16, Páginas 645-654 [en línea][recuperado el 11.07.2022]. Recuperado de Internet (URL:<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858516/pdf/nhms-1054030.pdf>), 1759-4812; 1759-4810 (en línea), (DOI: 10.1038/s41585-019-0237-8) Ver página 645, resumen; página 648, figura 2; página 651, columna 1. *

Also Published As

Publication number Publication date
ES2919083A2 (es) 2022-07-21

Similar Documents

Publication Publication Date Title
IL265697A (en) Prostate cancer treatment
KR20180084772A (ko) 암 치료를 위한 조합 치료법
MA44612A (fr) Méthodes de traitement de cancers pédiatriques
MA45780A (fr) Méthodes de traitement du cancer de la prostate
KR20220035414A (ko) Claudin18 항체 및 암 치료 방법
SG11202007922XA (en) Methods for prostate cancer detection and treatment
GB201903546D0 (en) Cancer treatment
SG11202010793UA (en) Methods of treating cancer
IL304275A (en) Cancer treatment methods
IL279591A (en) Cancer treatment methods using combination therapy
IL280830A (en) Bracelets for use in cancer treatment methods
IL287652A (en) Cancer treatment
MA54868A (fr) Arn thérapeutique contre le cancer de la prostate
SG11202107017TA (en) Methods of treating cancer
IL285466A (en) Cancer treatment
IL281600A (en) Methods of treating cancer
IL277981A (en) Cancer treatment methods
DK3986897T3 (da) EGFR-hæmmer til cancerbehandling
SG11202102492PA (en) Combination therapy for the treatment of prostate cancer
ES2919083R1 (es) Métodos de tratamiento de cáncer de próstata
KR20220035379A (ko) 암 치료를 위한 조합 요법
IL288035A (en) Cancer treatment
IL285056A (en) Prostate cancer treatment methods based on molecular subtypes
IL290038A (en) Focal treatment of prostate cancer
IL308088A (en) Mestitinib for the treatment of castrate-resistant prostate cancer

Legal Events

Date Code Title Description
BA2A Patent application published

Ref document number: 2919083

Country of ref document: ES

Kind code of ref document: A2

Effective date: 20220721

EC2A Search report published

Ref document number: 2919083

Country of ref document: ES

Kind code of ref document: R1

Effective date: 20220718